How does FDA long-term follow-up (up to 15 years) affect a gene therapy company's insurance?

FDA guidance recommends long-term follow-up (LTFU) of subjects who receive certain gene therapies for as long as 15 years, because delayed adverse events - including insertional oncogenesis from integrating vectors - can appear long after administration. Clinically, LTFU is about safety monitoring. For insurance, it means the window in which a subject can attribute an injury to the product and file a claim extends far beyond the trial itself.

Clinical trial liability and products liability are typically written on a claims-made basis, meaning the policy in force when the claim is reported responds, not the policy in force when the injury occurred. If a gene therapy company lets its claims-made coverage lapse at trial close-out, a delayed injury reported five or ten years later has no policy to respond, even though the company was fully insured during the trial.

This is the single most important insurance consequence of the 15-year LTFU expectation, and it is where gene-therapy programs most often have a latent gap.

Two mechanisms close the gap. First, preserving the retroactive date: as the company renews or changes carriers, the new policy should reach back to cover work done since the original retroactive date, so there is no gap in the claims-made chain. Second, an extended reporting period (ERP or tail) purchased at any close-out, exit, or carrier change extends the window to report claims after the policy ends.

For gene therapy, the tail may need to run many years to align with the LTFU period, and it is materially more expensive than tail for other indications. Treating it as a planned, budgeted cost from the start - rather than a surprise at wind-down or acquisition - is the difference between a funded and an unfunded long-tail exposure.

The long tail becomes acute at inflection points: a program wind-down, a licensing deal, or an acquisition. Buyers and partners in CGT deals scrutinize whether the long-tail liability is funded, and an unfunded tail can affect deal terms. Planning the retroactive-date continuity and the tail budget early makes the company cleaner to transact and protects the founders and the estate of a wound-down program.